Jin Judy, Rosen Michael J, Blatnik Jeffrey, McGee Michael F, Williams Christina P, Marks Jeffrey, Ponsky Jeffrey
Department of Surgery, University Hospitals Case Medical Center, Case School of Medicine, Cleveland, OH 44106, USA.
J Am Coll Surg. 2007 Nov;205(5):654-60. doi: 10.1016/j.jamcollsurg.2007.06.012. Epub 2007 Sep 14.
The ideal technique for the use of AlloDerm (LifeCell Corp) in complicated ventral hernia repair has not been defined. The expense of these products mandates careful evaluation to justify their widespread use. We compared two techniques of fascial bridging versus fascial reinforcement repair with regard to their longterm recurrence rates using AlloDerm.
We retrospectively studied patients with abdominal defects repaired with AlloDerm at our institution.
Thirty-seven patients with abdominal wall repairs using AlloDerm were identified between January 2004 and December 2005. Eleven patients underwent bridged fascial repair; 26 patients had reinforced fascial repair. There was no statistical significance between the 2 groups in terms of average age (57 versus 52 years), body mass index (35 versus 29 kg/m(2)), American Society of Anesthesiologists score (2.9 versus 2.5), or number of earlier abdominal operations (3.4 versus 3.5). The average sizes of AlloDerm used were 175 cm(2) for bridged and 89 cm(2) for reinforced repair (p=0.005). In patients with reinforced closure, primary repair was achieved with lateral component separation in 22 of 26 patients. Mean followup was 21.4 months (range 15 to 36 months). In the bridged group, 1 patient died on postoperative day 20. Of the remaining 10 patients, 8 patients (80%) developed recurrences. Seven patients required reoperation, but one patient refused repair. In the reinforced group, four patients were lost to followup and two patients died. Four of the remaining 20 patients (20%) developed recurrences that required repair; this was significantly different from the recurrence rate in the bridged group (p=0.009).
This study demonstrated that the method in which AlloDerm is used in abdominal wall reconstruction has a significant impact on recurrence rates. Based on our findings, AlloDerm should be used only as a reinforcement after primary fascial reappoximation.
在复杂的腹疝修补术中使用AlloDerm(LifeCell公司)的理想技术尚未明确。这些产品的费用要求进行仔细评估,以证明其广泛应用的合理性。我们比较了两种使用AlloDerm的筋膜桥接与筋膜加强修补技术的长期复发率。
我们回顾性研究了在我们机构接受AlloDerm修补腹壁缺损的患者。
2004年1月至2005年12月期间,共确定了37例使用AlloDerm进行腹壁修补的患者。11例患者接受了桥接筋膜修补;26例患者进行了加强筋膜修补。两组在平均年龄(57岁对52岁)、体重指数(35对29kg/m²)、美国麻醉医师协会评分(2.9对2.5)或既往腹部手术次数(3.4对3.5)方面无统计学差异。桥接修补使用的AlloDerm平均面积为175cm²,加强修补为89cm²(p = 0.005)。在加强缝合的患者中,26例患者中有22例通过外侧成分分离实现了一期修补。平均随访时间为21.4个月(范围15至36个月)。在桥接组中,1例患者在术后第20天死亡。其余10例患者中,8例(80%)出现复发。7例患者需要再次手术,但1例患者拒绝修补。在加强组中,4例患者失访,2例患者死亡。其余20例患者中有4例(20%)出现复发需要修补;这与桥接组的复发率有显著差异(p = 0.009)。
本研究表明,AlloDerm在腹壁重建中的使用方法对复发率有显著影响。根据我们的研究结果,AlloDerm应仅在一期筋膜重新缝合后用作加强材料。